No products in the cart.
Novavax’s coronavirus vaccine has been shown to be 90.4 percent effective in preventing COVID-19 cases, putting it on the same level as highly potent mRNA shots, the company announced on Monday.
The protein-based vaccine was also shown in Phase 3 studies to be 100 percent effective in preventing moderate and severe illness.
The studies, which enrolled 29,960 people in the US and Mexico, were conducted as more communicable variants spread and the alpha variant first discovered in the UK became dominant in the US percent – against new variants, the publication found.
The company also said its vaccine – which doesn’t need to be stored at extremely low temperatures – is 100 percent effective against the previous virus variants.
Novavax will submit its vaccine candidate for regulatory approval in the third quarter of the year. The company aims to produce 100 million cans per month by the end of the year. It will produce 150 million cans per month by the end of 2021.
However, limited production capacities in Europe prevented a purchasing contract with the EU. The Commission and the company concluded “exploratory talks” in December to purchase up to 200 million cans, but have not yet closed a deal.
This article is part of POLITICS‘s Premium Policy Service: Pro Health Care. Whether drug prices, EMA, vaccines, pharmaceuticals and more – our specialist journalists keep you up to date on health policy issues. E-mail [email protected] for a free trial.